15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Fennec Pharmaceuticals Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $13.00 to $18.00, so the covering firms are broadly aligned. The average target of $15.25 sits 54% above the current $9.93. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.11 next quarter toward $0.89 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Strong Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Fennec Pharmaceuticals Inc.
As of Jul, 4 of 4 firms rate FENC a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
FENC EPS & revenue forecast
EPS · NEXT QUARTER
$0.11
Range $0.06 – $0.17 · 5 analysts · -660% YoY
Next period, 5 analysts expect Fennec Pharmaceuticals Inc to earn $0.11 a share (range $0.06 – $0.17), versus $-0.02 a year earlier. Full-year consensus is $0.30, growing to $0.89 the year after.
REVENUE · NEXT QUARTER
$18.4M
Range $17.5M – $20.0M · 5 analysts · +48% YoY
Revenue is expected to reach $18.4M (range $17.5M – $20.0M), +47.7% year-over-year. Full-year consensus is $69.8M, rising to $100.4M next year.
Top analysts covering Fennec Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on FENC.
#1
Chase Knickerbocker
Craig-Hallum · Rank #25
Buy
No targeton FENC
Overall win rate
58%
+ Follow
#2
David Amsellem
Piper Sandler · Rank #95
Buy
$18.00+81.3% to target
Overall win rate
50%
+ Follow
#3
David Nierengarten
Wedbush · Rank #115
Buy
$13.00+30.9% to target
Overall win rate
41%
+ Follow
#4
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$16.00+61.1% to target
Overall win rate
37%
+ Follow
#5
Jason McCarthy
Maxim Group · Rank #360
Buy
$15.00+51.1% to target
Overall win rate
30%
+ Follow
FENC stock forecast FAQ
What is FENC's average 12-month price target?+
The 4 analysts with a live target average $15.25 for Fennec Pharmaceuticals Inc over the next 12 months, ranging from a $18.00 high to a $13.00 low.
Is FENC stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for FENC?+
The Street-high target is $18.00 (Piper Sandler), and the Street-low is $13.00 (Wedbush). The average of all 4 active targets is $15.25.
How many Wall Street analysts cover FENC?+
4 analysts have an active rating on Fennec Pharmaceuticals Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering FENC?+
Among analysts who currently cover FENC, Chase Knickerbocker of Craig-Hallum has the strongest overall Quantellect track record (Rank #25). Their current call is Buy.
What is Fennec Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.11 per share (range $0.06 – $0.17) across 5 analysts. Full-year EPS is projected at $0.30, rising to $0.89 the following year.
How much revenue is Fennec Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $18.4M (range $17.5M – $20.0M). Full-year revenue is projected at $69.8M, growing to $100.4M next year.
Have analysts been upgrading or downgrading FENC lately?+
As of Jul, 4 of 4 firms rate FENC a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their FENC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
